Skip to content
Sorrento Therapeutics’ (SRNE) competitors might be further down the line with their COVID-19 programs, but H.C. Wainwright analyst Ram Selvaraju highlights two separate routes the biotech could take to bring possible treatments and/or preventative therapies to market.Last week, Sorrento disclosed that in preclinical trials, the company’s monoclonal antibody (MaB), STI-4938, code named COVIDTRAP, inhibited SARS-CoV-2 viral infection in vitro.The data showed that STI-4938, an ACE2-Fc decoy protein, binds solidly to the SARS-CoV-2 virus spike protein, and is able to stop the virus from infecting the respiratory cells (specifically, in African green monkey kidney epithelial cells).Sorrento has another antibody in development, STI-1499 (COVI-SHIELD), which also recently demonstrated promising in vitro results as it was able to completely block the SARS-CoV-2 virus.While it is still early on for both antibodies, with the next stage involving preclinical animal studies, Selvaraju is encouraged by the additional positive results. “Together with Sorrento's previously announced preclinical neutralizing...
The financial regulations require hedge funds and wealthy investors that exceeded the $100 million equity holdings threshold to file a report that shows their positions at the end of every quarter. Even though it isn't the intention, these filings to a certain extent level the playing field for ordinary investors. The latest round of 13F […]...
Miller Value Partners recently released its Q1 2020 Investor Letter, a copy of which you can download below. The Miller Value Partners Opportunity Equity Fund posted a return of -38.4% for the quarter (net of fees), underperforming its benchmark, the S&P 500 Index which returned -19.6% in the same quarter. You should check out Miller […]...
This lawsuit focuses on 80 topical generic drugs, including creams, gels and ointments, which have billions in dollars of U.S. sales. It accuses Novartis unit Sandoz, Teva generic unit Actavis, Mylan Inc, Pfizer and other companies of breaking antitrust law by dividing up markets and rigging bids, according to statements from the attorneys general....
The lawsuit accused Novartis' Sandoz unit, Teva Pharmaceuticals' Actavis unit, Mylan, Pfizer Inc and other drugmakers of conspiring to rig the market between 2009 and 2016 for more than 80 drugs. Attorneys general from 46 states, the District of Columbia and four U.S. territories said the defendants prioritized profit over the public interest, depriving millions of consumers of lower prices for needed medication....
A hot tip to the former vice president from one former Federal Reserve governor....
Treasury Secretary Steven Mnuchin believes the U.S. economy will need more help to pull out of the recession, but said the next round of support should be more targeted to the hardest hit parts of the economy. Congress has already approved close to $3 trillion in support to deal with the impact of the coronavirus, which has resulted in millions of layoffs and has pushed the country into recession. “There is no question that small businesses in many industries will need more help,” Mnuchin said....
